ISCF Leading-edge Healthcare funding adds to range of sector opportunities
¬£197 million to develop first-of-a-kind technologies that will speed up patient access to new medicines.
Government aims to build on exporting strength of UK biopharmaceuticals.
Business Secretary Greg Clark today launched a comprehensive¬†funding programme¬†in leading-edge healthcare¬†- part of the Industrial Strategy Challenge Fund¬†investments first announced in April 2017.
The Leading-Edge Healthcare challenge was launched alongside a proposed¬†life sciences strategy from Professor Sir John Bell¬†which sets¬†out industry recommendations for the long-term success of UK life sciences; including¬†the establishment of the Healthcare Advanced Research Program (HARP), through which UK-based industries, charities and the NHS can work together to create new and more efficient ways of delivering sustainable healthcare.
The Leading-Edge Healthcare programme represents an investment of ¬£197 million over 4 years to develop first-of-a-kind technologies for the manufacture of medicines that will speed up patient access to new drugs and treatments,¬†improve public health and build the export strength of the UK‚Äôs biopharmaceutical sector. Elements will include:
¬∑ ¬† ¬† ¬†¬£66m for a Vaccines Development and Manufacturing Centre in partnership with industry,¬†to develop and manufacture vaccines for routine clinical trials and for emergency preparedness for epidemic threats.
¬∑ ¬† ¬† ¬†¬£13m for a Medicines Manufacturing Innovation Centre¬†in partnership with industry, to accelerate the adoption of emerging and novel manufacturing technologies and to transform fine chemical/pharmaceutical manufacturing
¬∑ ¬† ¬† ¬†¬£30m for a small network of Advanced Therapy Treatment Centres,¬†which will be based in hospitals and will transform the UK‚Äôs ability to develop and deliver cell and gene therapies at scale to large numbers of patients
¬∑ ¬† ¬† A ¬£25m collaborative R&D innovation competition to support SMEs working in these areas.
Leading-edge Healthcare programme funding will also double the manufacturing capacity of the Cell and Gene Therapy Manufacturing Centre in Stevenage.
This initiative adds to the healthcare sector¬†opportunities¬†already open through the Digital Catalyst competition¬†- a ¬£35m funding programme to be delivered¬†through the Industrial Strategy Challenge Fund over the next 4 years – and the ¬£10m Biomedical Catalyst Round 3, which supports the development of technologies and processes including disease prevention, early detection and tailored treatments.
KTN will host briefing events¬†as follows: see our events pages for more details and to make a booking.
- Medicines Manufacturing Round 1: Challenge Fund
¬£15m competition for collaborative R&D innovation funding through a competition to support SMEs working in these areas
Competition Briefing Event: 13 September, Manchester (you can also listen to a live webinar)
- Vaccines Development and Manufacturing Centre
To develop and manufacture vaccines for clinical trials and prepare for emergency epidemic threats, the government is investing ¬£66m in a new centre of excellence.
Competition¬†Briefing Event: 25 September, London
- Medicines Manufacturing Innovation Centre
A ¬£13m competition to establish a new centre, in partnership with industry, that will accelerate the adoption of emerging and novel technologies.
Competition Briefing event: 21 September, Glasgow
- Advanced Therapies Treatment Centre
¬£30m investment to establish a network of three centres, based in hospitals, that will transform the UK‚Äôs ability to develop and deliver cell and gene therapies to a larger number of patients.
Competition Briefing event: 26 September, York